The effects of a combined alpha- and beta-blocking drug, labetalol, on some aspects of platelet function.
The effects of the combined alpha- and beta-adrenoreceptor blocking agent labetalol on human blood platelets as estimated by platelet aggregation, platelet count, bleeding time and platelet factor 3 activity were studied in 5 patients. The drug reduced adrenaline-induced platelet aggregation in vitro. However, it did not influence the above platelet function test in therapeutic plasma concentrations in vivo.
D000328:Adult; D001792:Blood Platelets / Q000187:drug effects*; D001794:Blood Pressure / Q000187:drug effects; D004983:Ethanolamines / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007741:Labetalol / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D010977:Platelet Factor 3 / Q000378:metabolism; D011433:Propranolol / Q000494:pharmacology
D004983:Ethanolamines; D010977:Platelet Factor 3; D011433:Propranolol; D007741:Labetalol